Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Serum combination marker for evaluating gliclazide applicability of type 2 diabetes mellitus and detection kit thereof

A type 2 diabetes, applicability technology used in analytical chemistry and clinical medicine and medicine to achieve good repeatability, improved data quality, and high sensitivity

Active Publication Date: 2019-04-26
DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, no studies have used galactose, 5,8,11,14,17-eicosapentaenoic acid, methyl 8,11,14-eicosatrienoate, and methyl palmitate as combined markers Applicability evaluation of gliclazide in the treatment of type 2 diabetes mellitus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Serum combination marker for evaluating gliclazide applicability of type 2 diabetes mellitus and detection kit thereof
  • Serum combination marker for evaluating gliclazide applicability of type 2 diabetes mellitus and detection kit thereof
  • Serum combination marker for evaluating gliclazide applicability of type 2 diabetes mellitus and detection kit thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] 1. Serum sample collection

[0033] Before the collection of serum samples, all volunteers included in the study signed the informed consent.

[0034] Including 100 patients with newly diagnosed type 2 diabetes, the diagnosis of type 2 diabetes refers to the criteria of the World Health Organization [Reference 10: Alberti, K.; Zimmet, P.Z.; Consultation, W.H.O. 1998, 15(7), 539-553]. Patients with type 1 diabetes, mitochondrial diabetes, or those taking antidiabetic drugs were excluded, as were patients with pregnancy, cancer, heart failure, or renal failure. After a 2-week lead-in period (diet and exercise only), 100 patients started treatment with gliclazide sustained-release tablets (baseline), and were followed up and evaluated clinically at weeks 2, 4, 8, 12, and 16. During this period, 10 patients were excluded because they did not complete the full course of treatment, and a total of 90 patients eventually completed 16 weeks of gliclazide treatment. Baseline se...

Embodiment 2

[0049] 1. Serum sample collection

[0050] Before the collection of serum samples, all volunteers included in the study signed the informed consent.

[0051]Including 26 patients with newly diagnosed type 2 diabetes, the diagnosis of type 2 diabetes refers to the criteria of the World Health Organization [Reference 10: Alberti, K.; Zimmet, P.Z.; Consultation, W.H.O. 1998, 15(7), 539-553]. Patients with type 1 diabetes, mitochondrial diabetes, or those taking antidiabetic drugs were excluded, as were patients with pregnancy, cancer, heart failure, or renal failure. After a 2-week lead-in period (diet and exercise only), 26 patients started treatment with gliclazide sustained-release tablets (baseline), and were followed up and evaluated clinically at weeks 2, 4, 8, 12, and 16. Baseline serum samples were collected from patients and stored in a -80°C refrigerator for future use.

[0052] 2. Analysis method

[0053] With embodiment 1.

[0054] 3. Serum test results and auxili...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention relates to a serum combination marker for evaluating the gliclazide applicability of type 2 diabetes mellitus and a detection kit thereof, in particular to novel application of small-molecule metabolites, namely galactose, 5,8,11,14,17-eicosapentaenoic acid, 8,11,14-epoxyeicosatrienoic acid methyl ester and methyl palmitate, in serum samples in preparing the kit used for evaluating the gliclazide applicability of subjects as combination markers. The invention further relates to a kit for detecting patients remarkably responding to gliclazide in the subjects. By detecting relativeconcentrations of the combination markers in the serum samples of the subjects, the variables of the combination markers are calculated on the basis of a binary logic regression equation, and then onthe basis of determined section values, whether or not the subjects are suitable for gliclazide treatment is judged. The kit can achieve high-sensitivity high-efficiency detection of the small-molecule metabolites, and has the advantages of being low in detection cost, good in repeatability and high in diagnosis sensitivity.

Description

technical field [0001] The invention relates to a serum combination marker and a detection kit for evaluating the applicability of gliclazide for type 2 diabetes. It belongs to the fields of analytical chemistry, clinical medicine and medicine. Background technique [0002] Sulfonylureas, which stimulate endogenous insulin secretion mainly by binding to sulfonylurea receptors in pancreatic β-cells, are currently one of the main oral anti-glucose drugs for the treatment of type 2 diabetes mellitus (T2DM). Compared with the placebo group, sulfonylurea monotherapy reduced glycated hemoglobin (glycated hemoglobin, HbA1c (%)) by 1.51 [Reference 1: Hirst J.A., Farmer A.J., Dyar A., ​​Lung T.W.C., StevensR.J.Diabetologia, 2013, 56(5):973-984]. Gliclazide modified-release (gliclazide MR), one of the sulfonylureas, has good blood sugar control effect and fewer hypoglycemic events. In clinical practice, most T2DM patients can get good blood sugar control by using sulfonylureas, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/88G01N30/06
CPCG01N30/06G01N30/88
Inventor 许国旺周洋赵欣捷路鑫
Owner DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com